Janus Henderson Group plc Reports New 13.1% Stake in Bright Minds Biosciences Inc.

Janus Henderson Group plc filed a Schedule 13G/A on May 15, 2026, reporting a significant new position in Bright Minds Biosciences Inc. (DRUG). As of the event date of March 31, 2026, the filer beneficially owns 1,284,324 shares of common stock, representing a 13.1% ownership stake in the company. This marks a substantial increase from a previously reported 0% position. Janus Henderson Group plc acts as the ultimate parent company for several SEC-registered investment advisers, including Janus Henderson Investors US LLC and Janus Henderson Investors UK Limited, which exercise investment and voting discretion over the shares on behalf of managed portfolios. Specifically, the Janus Henderson Biotech Innovation Master Fund Ltd. was identified as having the right to receive dividends or proceeds from more than 5% of the common stock. The filing indicates that these shares were acquired in the ordinary course of business and are not held for the purpose of influencing or changing the control of the issuer.